ELITE COMPREHENSIVE
BIOPHARMACEUTICS (BLUE PACOP)
COMPREHENSIVE EXAMINATION
Biopharmaceutics and Pharmacokinetics
Practice Questions and Answers
Spring Examination May 2026
To achieve the same steady-state plasma concentration (for a drug that is excreted by
the kidney) in renal failure patients with normal renal function, you should
a. Increasing the dosing interval
b. Decrease the dose
c. Adjust both the dose and dosing interval
d. do any of the above, depending on pharmacodynamic properties of the drug
e. not adjust the dosing regimen unless the patient shows sign of toxicity
✓ d. do any of the above, depending on pharmacodynamic properties of
the drug
1
Which of the following factors make it necessary to give lower doses of drugs to
Page
geriatric patients?
, a. Reduced enzyme activity d. A and B only
b. Reduced kidney function e. A, B and C
c. Enhanced absorption
✓ d. A and B only
The Noyes-Whitney Equation describes
a. Zero-order kinetics d. dissolution rate
b. First-order kinetics e. renal clearance
c. Mixed-order kinetics
✓ d. dissolution rate
A prime consideration in biopharmaceutics is a drug's "bioavailability" which refers to the
relative amount of drug that reaches the
a. Small intestine d. liver
b. Stomach e. kidneys
c. Systemic circulation
✓ c. Systemic circulation
The AUC can be described as
I. A theoretical value
II. A measure of drug concentration-time curve
III. Having units of weight and time.volume
2
Page
a. I only d. II and III only
, b. III only e. AOTA
c. I and II only
✓ d. II and III only
What is the potentially first rate-limiting process when a tablet dosage form is
administered?
a. Ionization of the drug
b. Diffusion of the through the GI epithelium
c. Dissolution of the drug in the GI fluids
d. dissolution of the drug in the blood
e. disintegration in the tablet
✓ e. disintegration in the tablet
Which of the following could be the rate-limiting steps for drug absorption from an orally
administered drug product?
I. Disintegration of the unit
II. Dissolution of the active drug
III. Diffusion of the active drug through the intestinal wall
a. I only d. II and III only
b. III only e. AOTA
c. I and II only
✓ e. AOTA
3
Page
, The AUC of a drug can be determined from a graph by using which of the following
methods?
I. Law of diminishing returns
II. Rule of nines
III. Trapezoidal rule
a. I only d. II and III only
b. III only e. AOTA
c. I and II only
✓ b. III only
The peak of the serum concentration versus time curve approximates the
a. Point in time when the maximum pharmacologic of the pharmacologic effect occurs.
b. Point in time when absorption and elimination e. point in time when the drug begins to
have equalized be metabolized.
c. Maximum concentration of free drug in the urine.
d. time required for essentially all drug to be absorbed from the GI tract.
✓ b. Point in time when absorption and elimination
In which of the following sites may drugs be metabolized?
I. Skin
II. Lungs
III. Liver
4
Page
a. I only d. II and III only
BIOPHARMACEUTICS (BLUE PACOP)
COMPREHENSIVE EXAMINATION
Biopharmaceutics and Pharmacokinetics
Practice Questions and Answers
Spring Examination May 2026
To achieve the same steady-state plasma concentration (for a drug that is excreted by
the kidney) in renal failure patients with normal renal function, you should
a. Increasing the dosing interval
b. Decrease the dose
c. Adjust both the dose and dosing interval
d. do any of the above, depending on pharmacodynamic properties of the drug
e. not adjust the dosing regimen unless the patient shows sign of toxicity
✓ d. do any of the above, depending on pharmacodynamic properties of
the drug
1
Which of the following factors make it necessary to give lower doses of drugs to
Page
geriatric patients?
, a. Reduced enzyme activity d. A and B only
b. Reduced kidney function e. A, B and C
c. Enhanced absorption
✓ d. A and B only
The Noyes-Whitney Equation describes
a. Zero-order kinetics d. dissolution rate
b. First-order kinetics e. renal clearance
c. Mixed-order kinetics
✓ d. dissolution rate
A prime consideration in biopharmaceutics is a drug's "bioavailability" which refers to the
relative amount of drug that reaches the
a. Small intestine d. liver
b. Stomach e. kidneys
c. Systemic circulation
✓ c. Systemic circulation
The AUC can be described as
I. A theoretical value
II. A measure of drug concentration-time curve
III. Having units of weight and time.volume
2
Page
a. I only d. II and III only
, b. III only e. AOTA
c. I and II only
✓ d. II and III only
What is the potentially first rate-limiting process when a tablet dosage form is
administered?
a. Ionization of the drug
b. Diffusion of the through the GI epithelium
c. Dissolution of the drug in the GI fluids
d. dissolution of the drug in the blood
e. disintegration in the tablet
✓ e. disintegration in the tablet
Which of the following could be the rate-limiting steps for drug absorption from an orally
administered drug product?
I. Disintegration of the unit
II. Dissolution of the active drug
III. Diffusion of the active drug through the intestinal wall
a. I only d. II and III only
b. III only e. AOTA
c. I and II only
✓ e. AOTA
3
Page
, The AUC of a drug can be determined from a graph by using which of the following
methods?
I. Law of diminishing returns
II. Rule of nines
III. Trapezoidal rule
a. I only d. II and III only
b. III only e. AOTA
c. I and II only
✓ b. III only
The peak of the serum concentration versus time curve approximates the
a. Point in time when the maximum pharmacologic of the pharmacologic effect occurs.
b. Point in time when absorption and elimination e. point in time when the drug begins to
have equalized be metabolized.
c. Maximum concentration of free drug in the urine.
d. time required for essentially all drug to be absorbed from the GI tract.
✓ b. Point in time when absorption and elimination
In which of the following sites may drugs be metabolized?
I. Skin
II. Lungs
III. Liver
4
Page
a. I only d. II and III only
